We have recently isolated new peptides from probiotic bacteria with antibacterial effects on a range of pathogenic bacterial strains and their drug resistant derivatives . Our results show that in addition to be effective on antibiotic resistant bacteria isolated from mastitis infections, our patented bacteriocins shows synergy with traditional antibiotics and other commercial
bacteriocins, and reduces resistance development compared to single therapy. We have successfully developed a prototype formulation that efficiently kill Methicillin-resistant Staphylococcus aureus (MRSA) in a mouse infection model.